Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.60M | -100.74M | -86.91M | -79.73M | -76.69M |
| Total Depreciation and Amortization | 610.00K | 113.00K | 117.00K | 23.00K | 930.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.71M | 9.38M | 8.00M | 5.91M | 5.09M |
| Change in Net Operating Assets | -60.33M | 15.87M | -13.86M | 460.00K | 2.97M |
| Cash from Operations | -84.61M | -75.37M | -92.65M | -73.33M | -67.71M |
| Capital Expenditure | -127.00K | -42.00K | -86.00K | -114.00K | -293.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 126.20M | 75.76M | 100.15M | -62.80M | -84.37M |
| Cash from Investing | 126.08M | 75.72M | 100.06M | -62.92M | -84.67M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.07M | 764.00K | 9.42M | 36.83M | 235.18M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | 25.00M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -209.00K | 0.00 | -207.00K | -1.31M | -15.15M |
| Cash from Financing | 10.86M | 764.00K | 9.21M | 35.52M | 245.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.32M | 1.11M | 16.62M | -100.72M | 92.65M |